Chemistry:Quadrosilan
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Cisobitan |
| Other names | Quadrosilane; KABI-1774; 2,6-cisdiphenylhexa- methylcyclotetrasiloxane |
| Drug class | Nonsteroidal estrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H28O4Si4 |
| Molar mass | 420.758 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Quadrosilan (INN, BAN) (brand name Cisobitan; former developmental code name KABI-1774) is a synthetic nonsteroidal estrogen that was developed in the 1970s and that is or has been used as an antigonadotropic agent in the treatment of prostate cancer.[1][2][3][4] It is an organosilicon compound, and is also known as 2,6-cisdiphenylhexamethylcyclotetrasiloxane.[3][5] Quadrosilan has estrogenic activity equivalent to that of estradiol,[6] and can produce feminization and gynecomastia as side effects in male patients.[7][8]
See also
References
- ↑ The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014. pp. 629–. ISBN 978-1-4757-2085-3. https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA629.
- ↑ Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. 6 December 2012. pp. 243–. ISBN 978-94-011-4439-1. https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA243.
- ↑ 3.0 3.1 "Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study". Scandinavian Journal of Urology and Nephrology 17 (1): 37–43. 1983. doi:10.3109/00365598309179778. PMID 6346476.
- ↑ "Treatment of advanced cancer of the prostate". Seminars in Surgical Oncology 1 (1): 38–55. 1985. doi:10.1002/ssu.2980010106. PMID 3887539.
- ↑ The Chemistry of Organic Silicon Compounds. John Wiley & Sons Canada, Limited. 1989. p. 1154. ISBN 978-0-471-91993-3. https://books.google.com/books?id=cf4oAAAAYAAJ.
- ↑ "Exploitation of silicon medicinal chemistry in drug discovery". Expert Opinion on Investigational Drugs 13 (9): 1149–1157. September 2004. doi:10.1517/13543784.13.9.1149. PMID 15330746.
- ↑ "Biochemical Effects of 2, 6-cis-Diphenylhexamethylcyclotetrasiloxane in Man". Biochemistry of Silicon and Related Problems. 1978. pp. 515–520. doi:10.1007/978-1-4613-4018-8_23. ISBN 978-1-4613-4020-1.
- ↑ "Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan)". Scandinavian Journal of Urology and Nephrology 12 (1): 11–15. 1978. PMID 345431.
 |  |
